Repare Therapeutics

Repare Therapeutics has out-licensed its discovery platforms to newly-launched DCx Biotherapeutics for $4 million upfront plus equity stake and potential milestone payments, allowing Repare to focus on its clinical-stage oncology assets.

Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices.

Repare Therapeutics' shares fell 38% following Phase 1 results of lunresertib and camonsertib in endometrial and platinum-resistant ovarian cancers.

Repare Therapeutics' MYTHIC Phase 1 trial shows Lunre+Camo achieved a 25.9% ORR in endometrial cancer and 37.5% in platinum-resistant ovarian cancer.

Repare Therapeutics will present Phase 1 MYTHIC trial data for lunresertib combined with camonsertib in platinum-resistant ovarian and endometrial cancers.

Repare Therapeutics and the National Cancer Institute (NCI) have entered a Cooperative Research and Development Agreement (CRADA) to further develop camonsertib.

Repare Therapeutics is set to report Phase 2 dose expansion data for lunresertib plus camonsertib in platinum-resistant ovarian and endometrial cancers in December.

Repare Therapeutics presented data on an individualized dosing schedule of lunresertib and camonsertib in the Phase 1 MYTHIC trial.

Repare Therapeutics has dosed the first patient in its Phase I POLAR trial, evaluating RP-3467 as a treatment for advanced solid tumors.

Repare Therapeutics' camonsertib, an ATR inhibitor, combined with palliative radiation, demonstrates potential clinical benefits in metastatic tumors with ATM mutations.